BioVinc
Private Company
Funding information not available
Overview
BioVinc is a clinical-stage biotech pioneering a bone-selective drug delivery platform to address critical unmet needs in skeletal diseases, with an initial focus on prosthetic joint infections (PJI). The company's core technology utilizes bisphosphonate-based 'smart targeting' to concentrate therapeutics at the bone site, improving efficacy and reducing systemic side effects. Its lead program, OsteoFloxacin™, is an antibiotic conjugate in the pre-clinical/IND-enabling stage, positioned as a potential cure for PJI with eligibility for orphan drug designation. Founded in 2008 and built on decades of bisphosphonate research expertise, BioVinc is advancing a pipeline that could expand into other bone-related conditions, including cancer and arthritis.
Technology Platform
Proprietary bone-targeting platform using bisphosphonate-based 'smart targeting' and linker technology to selectively deliver therapeutic payloads (e.g., antibiotics) to bone disease sites, limiting systemic exposure.
Opportunities
Risk Factors
Competitive Landscape
While bisphosphonate targeting is well-established, BioVinc's specific antibiotic conjugate for PJI appears novel. Competition may come from other local antibiotic delivery systems, antimicrobial implant coatings, and systemic antibiotics. In broader bone-targeting, companies like Radius Health (with bone-targeted radiopharmaceuticals) operate in adjacent spaces.